Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2016

View Archived Issues

AS03-adjuvanted GlaxoSmithKline H7N9 pandemic influenza vaccine induces robust antibody responses

REDUCE-IT study of Amarin's Vascepa to continue as planned

Medicines for Malaria Venture initiates first-in-human trial of P-218

Circle Pharma and Pfizer enter agreement to build screening library of macrocyclic peptides

Bioblast Pharma reports results from extension study of trehalose in OPMD

Voyager Therapeutics enters collaboration to advance VY-HTT01 program

Semma Therapeutics receives grant for personalized cell therapy for diabetes

Phase II study of Flex Pharma's FLX-787 in ALS begins

FDA awards fast track designation to Aptinyx's NYX-2925

Ligand Pharmaceuticals initiates phase II study of LGD-6972

AmpliPhi Biosciences's AB-SA01 well tolerated in phase I study

Oxford Gene Technology launches new FISH probes for lung cancers

MMRF and Memorial Sloan Kettering collaborate on minimal residue disease trial

ANA positivity combined with anti-DFS70 negativity may be associated with CTD in NSIP patients

Dual GLP-1R/glucagon receptor agonist MOD-6031 enters phase I development for obesity

Morphotek and Fox Chase Cancer Center enter research agreement

European Commission approves Cabometyx for advanced renal cell carcinoma

CDRD launches new company developing novel rapid sepsis diagnostic

Cellectar Biosciences' CLR-131 to be evaluated in head and neck cancers

BioChaperone Combo reduces postprandial glucose and hyperglycemia risk in type 1 diabetes

MicroRNA 132 can be targeted to improve pressure-induced heart failure

Nanobiotix files for approval of NBTXR-3 in Europe

Hexanal shows potential as an inflammation biomarker

Bayer's emodepside granted U.S. orphan status for onchocerciasis

5-HETE and 5-oxoETE show potential for OSA screening

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.